Physician profile
Eric N Subong
NPI 1396788725
$12,746.34
in general payments reported to CMS, 2019-2025
22 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $742 · 2021: $644 · 2022: $6,190 · 2023: $780 · 2024: $1,684 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6,448.17 | 2019-2025 | Vabysmo, Lucentis, Susvimo |
| Alimera Sciences, INC. | $2,399.94 | 2019-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $1,227.20 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $351.13 | 2023-2025 | Syfovre |
| Abbvie INC. | $289.97 | 2024-2025 | |
| Alcon Vision LLC | $271.42 | 2023-2024 | Constellation |
| Eyepoint US, INC. | $265.83 | 2020-2023 | |
| Astellas Pharma US INC | $252.13 | 2024-2025 | Izervay |
| Biogen, INC. | $200.85 | 2022-2023 | Avonex |
| Carl Zeiss Meditec USA, INC. | $189.25 | 2021-2024 | Cirrus Hd-Oct |
| Dutch Ophthalmic, USA | $177.37 | 2020 | |
| Novartis Pharmaceuticals Corporation | $117.08 | 2019 | |
| Carl Zeiss Meditec, INC. | $102.51 | 2019 | |
| Ani Pharmaceuticals, INC. | $83.84 | 2025 | Purified Cortrophin Gel, Iluvien |
| Harrow Eye, LLC | $83.13 | 2025 | Iheezo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $77.26 | 2019-2021 | |
| Allergan, INC. | $71.86 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $43.54 | 2022-2023 | Xipere, Visudyne |
| Mallinckrodt Hospital Products INC. | $31.99 | 2025 | Acthar |
| Coherus Oncology, INC. | $22.16 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.31 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Subong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.